制药(BK4007)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK4007 制药

未开盘 06-01 16:00:00 EDT

852.23

-19.40

-2.23%

最高871.64	最低847.47	成交量3.15亿
今开871.64	昨收871.63	日振幅2.77%
总市值0.00	流通市值0.00	总股本0.00
成交额130.19亿	换手率--	流通股本0.00
市净率5.296022	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BK4007","market":"US","secType":"PLATE","nameCN":"制药","latestPrice":852.2341,"timestamp":1780343999999,"preClose":871.6317,"halted":0,"volume":314537744,"delay":0,"changeRate":-0.022254,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-19.397644,"latestTime":"06-01 16:00:00 EDT","open":871.6434,"high":871.6434,"low":847.4667,"amount":13019026797.246967,"amplitude":0.027737,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780407000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.296022,"peRate":26.721654,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK4007","defaultTab":"news","newsList":[{"id":"1170665076","title":"代理咨询机构ISS建议支持帕西拉生物科学所有董事提名人选，反对Doma Perpetual全部提名人","url":"https://stock-news.laohu8.com/highlight/detail?id=1170665076","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170665076?lang=zh_cn&edition=full","pubTime":"2026-06-02 04:52","pubTimestamp":1780347136,"startTime":"0","endTime":"0","summary":"代理咨询机构机构股东服务公司(ISS)已发布建议，支持帕西拉生物科学(Pacira Biosciences)提名的所有董事候选人，同时反对由Doma Perpetual提名的全部董事人选。这一关键建议为即将到来的股东投票提供了重要指引，或将影响公司董事会未来的构成与决策方向。帕西拉生物科学专注于非阿片类疼痛管理及再生医学领域，其董事会席位的归属备受市场关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105534675","title":"Fulcrum Therapeutics宣布终止镰状细胞病Pociredir项目并启动战略评估","url":"https://stock-news.laohu8.com/highlight/detail?id=1105534675","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105534675?lang=zh_cn&edition=full","pubTime":"2026-06-02 04:06","pubTimestamp":1780344395,"startTime":"0","endTime":"0","summary":"Fulcrum Therapeutics宣布，将终止其针对镰状细胞病的Pociredir研发项目，并同时启动一项全面的战略评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FULC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640954794","title":"Seaport Therapeutics将出席两大投资者会议，聚焦神经精神药物研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2640954794","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640954794?lang=zh_cn&edition=full","pubTime":"2026-06-01 21:09","pubTimestamp":1780319340,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics是一家专注于开发新型神经精神疾病疗法的临床阶段生物制药公司，近日宣布其管理团队将参与两场即将举行的投资者会议。　　根据公司发布的消息，Seaport将出席高盛第47届年度全球医疗保健会议，炉边谈话定于2026年6月10日上午8点举行。　　Seaport Therapeutics总部位于马萨诸塞州波士顿，于2024年成立，2026年5月1日在纳斯达克完成IPO上市，股票代码为SPTX。此次参与两大投资者会议，Seaport将向投资界分享其在神经精神药物研发领域的最新进展与战略规划。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-01/doc-inhzxmef5038397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4539","BK4007","SPTX","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130142441","title":"Edgewise 股价盘前飙升28% 拟将肌肉萎缩症业务以高达26.5亿美元出售给Servier","url":"https://stock-news.laohu8.com/highlight/detail?id=1130142441","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130142441?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:47","pubTimestamp":1780318039,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics 的股价在盘前交易时段大幅上涨28%。此前，该公司宣布已与法国制药公司Servier达成协议，将出售其肌肉萎缩症业务，交易总价值最高可达26.5亿美元。这笔交易预计将为Edgewise带来可观的现金收益，并使其能够更专注于其他研发管线的推进。市场对此消息反应积极。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156761829","title":"Turn Therapeutics中期分析显示：无治疗相关严重不良事件或停药报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1156761829","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156761829?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:36","pubTimestamp":1780317397,"startTime":"0","endTime":"0","summary":"Turn Therapeutics（直接上市）发布的中期分析数据显示，其研究在本次评估中未报告任何与治疗相关的严重不良事件，亦未出现受试者因治疗原因而中止参与的情况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104129166","title":"Edgewise Therapeutics：按计划推进心力衰竭药物Edg-15400的二期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1104129166","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104129166?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:35","pubTimestamp":1780317301,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics公司宣布，其针对射血分数保留型心力衰竭（HFpEF）的候选药物Edg-15400，仍按既定时间表推进二期临床试验的启动工作。这一进展标志着公司在心血管疾病治疗领域的研发管线取得了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EWTX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187254341","title":"Edgewise Therapeutics预计融资将完全支持Edg-7500研发直至潜在获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1187254341","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187254341?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:32","pubTimestamp":1780317121,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics宣布，其最新融资所得预计将足以支持其核心候选药物Edg-7500的完整开发计划，直至该药物获得潜在的监管批准。这笔资金将为公司推进这一重要治疗项目的临床研究及后续工作提供充足的资源保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EWTX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161075148","title":"Edgewise Therapeutics：肌肉萎缩症业务员工将获Servier类似聘用邀约","url":"https://stock-news.laohu8.com/highlight/detail?id=1161075148","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161075148?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:31","pubTimestamp":1780317119,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics公司宣布，其肌肉萎缩症业务部门的员工将收到来自Servier公司的可比拟聘用邀约。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EWTX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169073939","title":"Edgewise Therapeutics将获15.5亿美元首付款，并有资格获得最高11亿美元的里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1169073939","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169073939?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:31","pubTimestamp":1780317076,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics宣布，公司将获得15.5亿美元的预付现金对价，并有资格根据后续开发与商业化进展，获得最高可达11亿美元的里程碑付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","EWTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178696214","title":"Turn Therapeutics公布Gx-03二期试验中期分析结果及中重度特应性皮炎适应症优化策略","url":"https://stock-news.laohu8.com/highlight/detail?id=1178696214","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178696214?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:30","pubTimestamp":1780317034,"startTime":"0","endTime":"0","summary":"Turn Therapeutics公布了其针对中重度特应性皮炎的Gx-03二期临床试验的中期分析结果，并同步披露了一项适应性优化策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124846858","title":"FDA优先审评施贵宝Camzyos补充新药申请，用于治疗青少年症状性梗阻性肥厚型心肌病","url":"https://stock-news.laohu8.com/highlight/detail?id=1124846858","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124846858?lang=zh_cn&edition=full","pubTime":"2026-06-01 19:00","pubTimestamp":1780311638,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局已接受施贵宝（Bristol-Myers Squibb）提交的Camzyos（Mavacamten）补充新药申请，并授予其优先审评资格。该申请旨在扩展该药物的适应症，用于治疗青少年患者的症状性梗阻性肥厚型心肌病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1670710661.SGD","LU0225771236.USD","LU1032466523.USD","BK4581","BK4534","IE0002141913.USD","LU1261432733.SGD","LU0114720955.EUR","LU1430594728.SGD","LU2360032135.SGD","LU0882574055.USD","IE0009355771.USD","LU0456855351.SGD","LU0321505868.SGD","LU0061475181.USD","LU1291159041.SGD","LU1868836914.USD","IE00BJJMRZ35.SGD","LU0225284248.USD","LU0096364046.USD","LU0306806265.USD","LU2125154935.USD","LU1323610961.USD","LU1868836591.USD","LU1868837136.USD","LU1718418525.SGD","IE00B2B36J28.USD","LU1571399168.USD","LU0306807586.USD","IE00BSNM7G36.USD","LU1989771016.USD","BK4007","BMY","LU0267386448.USD","LU0868494617.USD","LU1868836757.USD","LU1670711123.USD","LU1074936037.SGD","LU1868837300.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU1093756168.USD","LU2125154778.USD","LU2242646821.SGD","LU1983299246.USD","LU1670710588.SGD","BK4585","IE00BFXG1179.USD","LU0985481810.HKD","LU0237698245.USD","LU0321505439.SGD","LU1883839398.USD","LU2133065610.SGD","LU1093756325.SGD","LU2242652126.USD","LU1585245621.USD","BK4588","LU1670711040.USD","BK4559","BK4532","LU0432979614.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120138167","title":"施贵宝免疫疗法组合获批用于治疗既往未治疗的III/IV期经典霍奇金淋巴瘤成人与青少年患者（12岁及以上）","url":"https://stock-news.laohu8.com/highlight/detail?id=1120138167","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120138167?lang=zh_cn&edition=full","pubTime":"2026-06-01 18:59","pubTimestamp":1780311545,"startTime":"0","endTime":"0","summary":"施贵宝公司宣布，其免疫疗法组合方案已获得监管批准，适用于治疗既往未接受过治疗的III期或IV期经典霍奇金淋巴瘤（CHL）患者，覆盖年龄在12岁及以上的成人和青少年人群。这一批准标志着该疗法应用范围的进一步扩大，为更广泛的患者群体提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836757.USD","LU1718418525.SGD","BK4007","LU0267386448.USD","IE00BFTCPJ56.SGD","BK4559","IE00B2B36J28.USD","LU1074936037.SGD","IE00BSNM7G36.USD","IE00BFXG1179.USD","LU0225284248.USD","LU0237698245.USD","LU1032466523.USD","LU0432979614.USD","LU0306806265.USD","LU0882574055.USD","BK4532","LU1868836914.USD","LU1983299246.USD","LU2125154778.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","LU1868836591.USD","LU2133065610.SGD","BK4581","LU1883839398.USD","LU0868494617.USD","LU1571399168.USD","BK4534","LU0096364046.USD","LU0114720955.EUR","LU1093756168.USD","LU1670710588.SGD","LU0456855351.SGD","LU1670711040.USD","BK4585","LU1868837300.USD","IE0002141913.USD","LU1585245621.USD","IE00BJT1NW94.SGD","LU0321505439.SGD","LU0321505868.SGD","LU2125154935.USD","LU0306807586.USD","BK4588","LU1093756325.SGD","BMY","LU1323610961.USD","LU1868837136.USD","LU1670710661.SGD","LU1261432733.SGD","LU1430594728.SGD","LU2360032135.SGD","LU1291159041.SGD","LU2242646821.SGD","LU0225771236.USD","LU1670711123.USD","LU0985481810.HKD","LU1989771016.USD","LU2242652126.USD","LU0061475181.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168315798","title":"施贵宝宣布欧狄沃®联合AVD疗法获欧盟扩大标签，获批用于一线治疗晚期经典型霍奇金淋巴瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1168315798","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168315798?lang=zh_cn&edition=full","pubTime":"2026-06-01 18:55","pubTimestamp":1780311348,"startTime":"0","endTime":"0","summary":"施贵宝宣布，其欧狄沃®（纳武利尤单抗）联合AVD化疗方案，已获得欧盟监管机构批准扩大标签，可用于一线治疗晚期经典型霍奇金淋巴瘤。这一决定标志着该免疫联合疗法在欧洲的应用范围得到进一步拓展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0432979614.USD","LU1093756168.USD","LU0237698245.USD","LU2125154935.USD","LU0267386448.USD","BK4007","LU1430594728.SGD","LU0114720955.EUR","LU0306806265.USD","LU1074936037.SGD","LU0225284248.USD","IE00BFXG1179.USD","LU1261432733.SGD","IE00BFTCPJ56.SGD","BK4532","LU0306807586.USD","LU1093756325.SGD","LU1291159041.SGD","LU0321505439.SGD","LU2125154778.USD","BK4581","LU1868836914.USD","IE00B2B36J28.USD","LU1585245621.USD","LU0882574055.USD","LU1718418525.SGD","IE0002141913.USD","LU2133065610.SGD","IE00BSNM7G36.USD","LU1868836757.USD","LU0985481810.HKD","LU1883839398.USD","IE0009355771.USD","LU2242652126.USD","LU0456855351.SGD","LU0321505868.SGD","LU1868837300.USD","BK4585","LU1670710661.SGD","LU2242646821.SGD","LU0061475181.USD","BK4588","IE00BJJMRZ35.SGD","LU1670711123.USD","LU1868836591.USD","LU1868837136.USD","LU0868494617.USD","BK4559","LU1571399168.USD","LU1670710588.SGD","LU1989771016.USD","LU1983299246.USD","LU0225771236.USD","LU1670711040.USD","LU0096364046.USD","LU1032466523.USD","IE00BJT1NW94.SGD","BMY","LU2360032135.SGD","BK4534","LU1323610961.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188845900","title":"海思科与礼来签署许可及研发合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1188845900","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188845900?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:08","pubTimestamp":1780304911,"startTime":"0","endTime":"0","summary":"海思科宣布，其子公司已与礼来公司签署了一项许可及研发合作协议。根据该协议，海思科有权获得总计高达8700万美元的首付款及近期款项。此外，协议还规定，后续基于里程碑的付款总额最高可达30亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868837300.USD","SG9999001176.USD","LU0672654240.SGD","LU2089984988.USD","LU0353189763.USD","LU0787776722.HKD","LU1712237335.SGD","LU1280957306.USD","LU1232071149.USD","LU0234572021.USD","SG9999014906.USD","LU1323610961.USD","ELIL","LU0006306889.USD","LU2168564149.EUR","LU2461242641.AUD","IE00B2B36J28.USD","IE00BJLML261.HKD","LU0203202063.USD","LU2237443622.USD","LU2746668461.USD","LU2756315664.SGD","IE00BKPKM429.USD","LU2237443465.HKD","IE00BFSS8Q28.SGD","LU0256863811.USD","LU2023250504.SGD","SG9999001176.SGD","LU0256863902.USD","LU1023059063.AUD","LU2360106947.USD","IE00B1XK9C88.USD","IE00B7KXQ091.USD","LU2602419157.SGD","SG9999014898.SGD","IE00BJT1NW94.SGD","BK0239","LU0320765059.SGD","SG9999018857.SGD","BK0077","LU2357305700.SGD","LU0456855351.SGD","LU0109391861.USD","LU2168563687.JPY","LU2168564222.USD","LU2237443978.SGD","LU2746668974.SGD","LU1868837136.USD","LU2089284900.SGD","LU0432979614.USD","LU2028103732.USD","LU0471298777.SGD","SG9999018865.SGD","BK4588","SG9999014914.USD","IE0002141913.USD","IE00B1BXHZ80.USD","SG9999017495.SGD","LU2462157665.USD","LU2063271972.USD","LU1069344957.HKD","LU2491049909.HKD","LU0820561818.USD","LU1551013342.USD","LU0323591593.USD","LU0889565916.HKD","LU1057294990.SGD","LU2552382132.HKD","LU1804176565.USD","LLYZ","SG9999015952.SGD","LLII","LU2112291526.USD","LU2168564065.EUR","LU2237438978.USD","SG9999015945.SGD","IE00BJJMRX11.SGD","LU1061106388.HKD","LU0094547139.USD","LU1291159041.SGD","IE00B4JS1V06.HKD","LU0823434740.USD","LU2361045086.USD","LU0820561909.HKD","GB00BDT5M118.USD","IE00BK4W5L77.USD","IE00BK4W5M84.HKD","LU1720051017.SGD","LU2471134523.USD","LU0689472784.USD","LU0943347566.SGD","LU0964807845.USD","LU2468319806.SGD","LU0385154629.USD","LU2552382215.SGD","LU1720051108.HKD","SGXZ31699556.SGD","LU1868836914.USD","LU0353189680.USD","SGXZ81514606.USD","LU1989771016.USD","LU2471134879.HKD","LU0354030438.USD","LU2089283258.USD","BK4581","SG9999014880.SGD","LU1093756325.SGD","IE0004445015.USD","LU0158827781.USD","LU2023250330.USD","IE00BJJMRY28.SGD","LU2106854487.HKD","IE0009355771.USD","LU0786609619.USD","LU2087625088.SGD","BK0188","002653","BK0033","IE00BKDWB100.SGD","LU0109394709.USD","BK4534","LU1974910355.USD","LU2417539215.USD","LU0210536198.USD","LU2108987350.USD","LU0882574139.USD","LU1988902786.USD","LU0316494557.USD","LU0289739699.SGD","LU1145028129.USD","LU0882574055.USD","IE0001KFT4U8.USD","IE0005OL40V9.USD","LU0133085943.USD","LU0354030511.USD","LU1093756168.USD","LLY","LU0683600562.USD","LU0471298694.HKD","LU0238689110.USD","LU1629891620.HKD","LU2456880835.USD","LU2361044949.HKD","IE00BFSS7M15.SGD","BK4533","LU1814569148.SGD","LU0417517546.SGD","LU0225283273.USD","IE0004445239.USD","LU0823416689.USD","BK4599","LU0096364046.USD","LU1551013425.SGD","LU2324357040.USD","LU2896262040.SGD","SGXZ99366536.SGD","LU0114720955.EUR","ELIS","BK4585","SGXZ57979304.SGD","LU2237443895.HKD","LU2237443382.USD","LU1868836591.USD","LU0106261372.USD","LU0320765992.SGD","LU2236285917.USD","LU2491050071.SGD","IE00BWXC8680.SGD","LU2552382058.USD","BK0028","LU2750360641.GBP","LU0061475181.USD","LU0640476718.USD","LU0466842654.USD","LU1366192091.USD","IE00BJJMRZ35.SGD","LU1127390331.HKD","BK4516","SGXZ51526630.SGD","BK4007","LU2211815571.USD","LU0708995401.HKD","LU1064131342.USD","LU2756315318.SGD","IE00B775H168.HKD","LLYX","SG9999015978.USD","SG9999015986.USD","LU2471134796.USD","IE00B4R5TH58.HKD","LU1623119135.USD","LU2168564495.EUR","LU2237443549.SGD","LU1983299246.USD","LU0820562030.AUD","LU2213496289.HKD","LU0266013472.USD","LU0203201768.USD","LU0058720904.USD","LU0122379950.USD","LU2361044865.SGD","IE00BFTCPJ56.SGD","LU2264538146.SGD","LU0097036916.USD","LU0823434583.USD","LU2271345857.HKD","LU1035775433.USD","SG9999013999.USD","LU1267930730.SGD","LU2491050154.USD","LU2750360997.AUD","LU2111349929.HKD","LU1868836757.USD","LU0079474960.USD","LU2471134952.CNY","LU2023251221.USD","IE00BN29S564.USD","LU1548497426.USD","LU0158827948.USD","LU1917777945.USD","LU2265009873.SGD","LU0198837287.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640693798","title":"海思科：与礼来签署研发合作协议，最高获8700万美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2640693798","media":"新京报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640693798?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:01","pubTimestamp":1780304513,"startTime":"0","endTime":"0","summary":"新京报贝壳财经讯6月1日，海思科公告，公司全资子公司海思科医药科技(拉萨)有限公司与礼来公司于2026年5月29日签署《授权与研发合作协议》，双方将在多个疾病领域开展最多五个靶点创新药项目的发现及早期研发合作。根据协议，公司有权获得最高8700万美元的首付款和近期付款，以及最高29.67亿美元的后续里程碑付款，并有权根据产品未来净销售额获得分级销售提成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606013756093946.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606013756093946.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00B1BXHZ80.USD","LU1974910355.USD","LLYZ","LU2168564495.EUR","LU0256863902.USD","LU0266013472.USD","LU2461242641.AUD","IE00BJJMRY28.SGD","LU2271345857.HKD","IE0004445015.USD","LU0289739699.SGD","SG9999015945.SGD","IE00B7KXQ091.USD","LU0943347566.SGD","LU1814569148.SGD","LU1323610961.USD","LU1023059063.AUD","LU2087625088.SGD","LU1868836914.USD","LU2471134952.CNY","BK4534","LU0820562030.AUD","LU2360106947.USD","LU0158827781.USD","LU1983299246.USD","LU2237438978.USD","LU0820561818.USD","LU0096364046.USD","LU2237443465.HKD","LU2237443622.USD","LU2357305700.SGD","LU1551013342.USD","LU2756315664.SGD","LU0471298777.SGD","IE00BWXC8680.SGD","LU2361044949.HKD","LU1057294990.SGD","SG9999014906.USD","LU2602419157.SGD","LU0234572021.USD","LU1804176565.USD","LU1623119135.USD","BK4599","LU0823434740.USD","LU2896262040.SGD","BK0077","LU2471134523.USD","LU0203201768.USD","LU2265009873.SGD","LU2746668974.SGD","LU0689472784.USD","LU1093756325.SGD","LU0097036916.USD","IE00B4R5TH58.HKD","LU1064131342.USD","LU0203202063.USD","LU2211815571.USD","LU0238689110.USD","IE00BFTCPJ56.SGD","LU0006306889.USD","LU1917777945.USD","SGXZ57979304.SGD","LU0353189680.USD","LU1035775433.USD","SG9999018857.SGD","LU2462157665.USD","LU2552382058.USD","LU0683600562.USD","LU0316494557.USD","LU1291159041.SGD","LU0882574055.USD","LU2237443978.SGD","LU2028103732.USD","LU0964807845.USD","LU0471298694.HKD","LU0109394709.USD","BK4588","LU2552382132.HKD","SGXZ51526630.SGD","IE00BK4W5L77.USD","LU1093756168.USD","LU1548497426.USD","LU1720051108.HKD","LU2750360997.AUD","LU0225283273.USD","SG9999001176.USD","LU1145028129.USD","LU2089984988.USD","LU2237443895.HKD","LU2361045086.USD","LU2491050154.USD","LU0114720955.EUR","SG9999001176.SGD","LU2106854487.HKD","LU0353189763.USD","IE00B2B36J28.USD","LU1868836757.USD","SG9999018865.SGD","IE00BJJMRX11.SGD","LU0079474960.USD","LU2023250330.USD","LU0672654240.SGD","LU1551013425.SGD","LU2552382215.SGD","BK4516","LU1712237335.SGD","LU0094547139.USD","LU1061106388.HKD","LU0456855351.SGD","LU2236285917.USD","BK4007","LU1629891620.HKD","002653","LU0823416689.USD","LU2023251221.USD","LLII","LU2471134879.HKD","LU1069344957.HKD","LU0256863811.USD","LU2491050071.SGD","BK0028","LU2471134796.USD","LU0354030511.USD","IE00BK4W5M84.HKD","LU0385154629.USD","LU0417517546.SGD","LU0158827948.USD","LU0323591593.USD","ELIS","IE0004445239.USD","BK4581","LLY","LU1280957306.USD","LU2746668461.USD","IE00BJT1NW94.SGD","LU0823434583.USD","LU2168564149.EUR","SG9999014880.SGD","BK4533","IE00B4JS1V06.HKD","IE00BJLML261.HKD","LU0820561909.HKD","ELIL","LU0882574139.USD","BK0239","LU0787776722.HKD","LU2361044865.SGD","LLYX","LU2108987350.USD","BK0188","IE00BFSS8Q28.SGD","LU2237443549.SGD","LU0889565916.HKD","SGXZ31699556.SGD","LU2324357040.USD","LU0122379950.USD","LU0786609619.USD","LU2111349929.HKD","SG9999013999.USD","LU1868837136.USD","LU1989771016.USD","LU1868836591.USD","LU1868837300.USD","LU0708995401.HKD","IE0001KFT4U8.USD","IE0005OL40V9.USD","LU0432979614.USD","IE00BFSS7M15.SGD","BK0033","IE00BKPKM429.USD","LU2237443382.USD","SG9999015986.USD","IE0009355771.USD","LU2089284900.SGD","LU2089283258.USD","LU1720051017.SGD","SG9999015952.SGD","LU2264538146.SGD","SGXZ99366536.SGD","SG9999014914.USD","IE00BJJMRZ35.SGD","SG9999017495.SGD","BK4585","LU2468319806.SGD","LU0640476718.USD","LU2023250504.SGD","IE00BKDWB100.SGD","LU0198837287.USD","IE0002141913.USD","LU2756315318.SGD","LU0109391861.USD","LU0106261372.USD","LU2168564065.EUR","LU2491049909.HKD","LU0061475181.USD","IE00BN29S564.USD","LU2112291526.USD","LU2168564222.USD","LU1267930730.SGD","IE00B775H168.HKD","LU0320765059.SGD","LU2456880835.USD","LU0210536198.USD","LU0058720904.USD","GB00BDT5M118.USD","LU2750360641.GBP","LU1127390331.HKD","LU0133085943.USD","IE00B1XK9C88.USD","LU1988902786.USD","LU2213496289.HKD","SG9999015978.USD","SGXZ81514606.USD","LU0354030438.USD","LU1366192091.USD","LU0466842654.USD","SG9999014898.SGD","LU2063271972.USD","LU2417539215.USD","LU2168563687.JPY","LU1232071149.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640330789","title":"【券商聚焦】中信建投维持信达生物(01801)“买入”评级 指其与辉瑞合作全球化里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2640330789","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640330789?lang=zh_cn&edition=full","pubTime":"2026-06-01 13:55","pubTimestamp":1780293323,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报指，信达生物 与辉瑞达成全球战略合作，交易总额达105亿美元。信达生物将获得首付款6.5亿美元，并有资格获得最高达98.5亿美元的研发、监管与商业化里程碑付款，对于每一款获批项目还将获得最高达双位数比例的销售分成。中信建投预计信达生物2026-2028年收入分别为180.2亿元、243.3亿元、285.8亿元，净利润分别为22.1亿元、38.2亿元、50.1亿元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1982638","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU2097828805.USD","LU1969619763.USD","SGXZ57979304.SGD","LU0321505868.SGD","LU0456855351.SGD","LU0868494617.USD","BK1583","BK4533","LU0170899867.USD","SG9999001176.USD","LU1066051498.USD","LU1894683348.USD","LU0455707207.USD","LU2097828631.EUR","LU0225771236.USD","LU1066053197.SGD","BK4581","IE00BLSP4239.USD","LU1057294990.SGD","LU1883839398.USD","PFE","SG9999011175.SGD","LU0225284248.USD","BK1161","SG9999003800.SGD","IE0002270589.USD","SG9999001176.SGD","LU0234572021.USD","IE00B19Z3B42.SGD","SG9999013999.USD","IE00B19Z3581.USD","BK1589","LU0306806265.USD","LU1894683264.USD","LU0321505439.SGD","LU2328871848.SGD","LU2488822045.USD","LU0122379950.USD","IE000M9KFDE8.USD","IE00BBT3K403.USD","LU0306807586.USD","LU0502904849.HKD","BK4550","BK4599","BK4585","BK4007","BK4568","LU2097828474.EUR","LU1023059063.AUD","LU0289739699.SGD","SG9999002232.USD","01801","IE00BLSP4452.SGD","LU0985481810.HKD","IE00B3T34201.USD","LU2097828557.USD","LU2242644610.SGD","BK4534","BK4592","LU2097828714.EUR","BK4588","SG9999002224.SGD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640339909","title":"Gate 股票衍生品专区将首发上线 NVO（诺和诺德）、NOK（诺基亚）等 6 个永续合约交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2640339909","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640339909?lang=zh_cn&edition=full","pubTime":"2026-06-01 13:39","pubTimestamp":1780292398,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据官方消息，Gate 股票衍生品专区将于 6 月 1 日 14:00（UTC+8）首发上线 NVO（诺和诺德）、NOK（诺基亚）、ASTS（AST 太空移动）、AAOI（应用光电）、INFQ (Infleqtion)、CRWD（众击）永续合约交易（USDT 结算），支持 1-20 倍杠杆。\n ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2268446","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154236417.USD","BK4599","IE00BMPRXR70.SGD","BK4020","BK4547","BK4007","LU1093756325.SGD","IE00BKVL7J92.USD","NVO","GATE","NVOX","BK4588","IE00BMPRXN33.USD","NOK","BK4532","NVOH","BK4585","IE00BZ1G4Q59.USD","LU1093756168.USD","LNOK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640298066","title":"礼来(LLY.US)靶向药物Retevmo在晚期临床试验中显著降低肺癌复发风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2640298066","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640298066?lang=zh_cn&edition=full","pubTime":"2026-06-01 11:32","pubTimestamp":1780284770,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，礼来表示，根据上周日在美国临床肿瘤学会年会上公布并同步发表于《新英格兰医学杂志》的Ⅲ期临床试验结果，其靶向抗癌药物Retevmo显著降低了早期RET融合阳性非小细胞肺癌患者的疾病复发或死亡风险。在24个月时，92%的selpercatinib治疗患者仍未发生疾病复发或死亡事件;安慰剂组这一比例为61%。目前，Retevmo已获美国批准用于部分晚期或转移性RET融合阳性肺癌患者治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448346.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SGXZ99366536.SGD","LU1988902786.USD","LU2112291526.USD","LU2324357040.USD","SGXZ81514606.USD","SG9999001176.USD","LU2746668461.USD","LU0122379950.USD","LU2087625088.SGD","LU2237443978.SGD","LU0097036916.USD","LU0234572021.USD","IE00B1XK9C88.USD","LU0096364046.USD","LU2471134879.HKD","LU1548497426.USD","LU2491050154.USD","LU1551013342.USD","SG9999014898.SGD","LU2168564495.EUR","IE00BK4W5M84.HKD","LU2756315664.SGD","LU1868837136.USD","IE00BN29S564.USD","LLYZ","LU2471134796.USD","LU2491050071.SGD","LU1804176565.USD","LU2023250504.SGD","IE00BJT1NW94.SGD","LU1366192091.USD","LU0289739699.SGD","LU2237443895.HKD","BK4534","LU0133085943.USD","LU0353189680.USD","LU2750360997.AUD","IE00BKDWB100.SGD","SG9999014906.USD","SGXZ51526630.SGD","LU2471134523.USD","GB00BDT5M118.USD","LU0820562030.AUD","LU2756315318.SGD","LU1868837300.USD","LU0964807845.USD","LU1023059063.AUD","LU2168564065.EUR","LU1127390331.HKD","LU0786609619.USD","LU2063271972.USD","LU0432979614.USD","LU2361045086.USD","LU0471298694.HKD","IE00B4R5TH58.HKD","LLY","LU0683600562.USD","SG9999015978.USD","LU0708995401.HKD","LU1868836591.USD","LLYX","LU1232071149.USD","LU0787776722.HKD","LU1720051017.SGD","LU1035775433.USD","LU1064131342.USD","IE00B775H168.HKD","LU0640476718.USD","LU0109394709.USD","SG9999015945.SGD","IE00BKPKM429.USD","LU2213496289.HKD","LU2168564149.EUR","SG9999018857.SGD","LU0889565916.HKD","LU2264538146.SGD","IE0004445239.USD","BK4585","LU0323591593.USD","LU2237443382.USD","IE00BJJMRX11.SGD","LU0106261372.USD","BK4581","IE00BJJMRZ35.SGD","LU0203201768.USD","BK4007","LU1868836914.USD","LU2360106947.USD","LU0256863811.USD","LU1267930730.SGD","LU0158827781.USD","LU2168564222.USD","LU0353189763.USD","LU0417517546.SGD","LU0466842654.USD","LU0689472784.USD","LU0823434740.USD","IE00BK4W5L77.USD","SG9999015986.USD","LU2168563687.JPY","LU2265009873.SGD","LU0456855351.SGD","LU1917777945.USD","LU2089284900.SGD","LU1069344957.HKD","IE0002141913.USD","SGXZ57979304.SGD","LU0354030438.USD","IE00BJLML261.HKD","LU2552382132.HKD","LU1057294990.SGD","SG9999001176.SGD","LU2462157665.USD","LU1093756168.USD","SG9999017495.SGD","SG9999014914.USD","LU1814569148.SGD","LU2468319806.SGD","LU0006306889.USD","LU0238689110.USD","IE00BJJMRY28.SGD","LU2357305700.SGD","LU2491049909.HKD","SG9999013999.USD","LU0198837287.USD","IE00B2B36J28.USD","LU0672654240.SGD","LU2023251221.USD","LU2106854487.HKD","LU1323610961.USD","LU0820561818.USD","LU1551013425.SGD","LU2028103732.USD","ELIL","LU2089984988.USD","LU0385154629.USD","LU0158827948.USD","IE0001KFT4U8.USD","LU0256863902.USD","LU0320765059.SGD","LU0316494557.USD","LU2237443622.USD","LU2456880835.USD","LU0820561909.HKD","LLII","LU1720051108.HKD","LU1291159041.SGD","LU2471134952.CNY","LU1712237335.SGD","LU0210536198.USD","IE0005OL40V9.USD","BK4516","LU2089283258.USD","SG9999015952.SGD","IE00BFTCPJ56.SGD","LU2211815571.USD","LU0354030511.USD","LU0079474960.USD","LU0266013472.USD","LU0823416689.USD","LU2417539215.USD","IE00B4JS1V06.HKD","LU0823434583.USD","LU2361044949.HKD","LU2552382058.USD","LU2111349929.HKD","LU2602419157.SGD","BK4533","LU0061475181.USD","LU2023250330.USD","LU2237443465.HKD","LU2750360641.GBP","BK4588","LU2237438978.USD","BK4599","LU1623119135.USD","LU0094547139.USD","LU2746668974.SGD","LU1280957306.USD","LU0225283273.USD","LU2237443549.SGD","SGXZ31699556.SGD","LU1983299246.USD","IE00B1BXHZ80.USD","LU1868836757.USD","IE00BFSS7M15.SGD","LU2552382215.SGD","LU0471298777.SGD","IE00BFSS8Q28.SGD","LU0320765992.SGD","LU1145028129.USD","SG9999018865.SGD","LU1989771016.USD","IE0009355771.USD","LU0882574139.USD","LU2236285917.USD","IE00B7KXQ091.USD","LU0203202063.USD","LU2361044865.SGD","IE00BWXC8680.SGD","LU1629891620.HKD","LU2896262040.SGD","LU2271345857.HKD","LU0058720904.USD","LU0943347566.SGD","LU1974910355.USD","SG9999014880.SGD","LU1093756325.SGD","ELIS","IE0004445015.USD","LU1061106388.HKD","LU0114720955.EUR","LU0882574055.USD","LU2461242641.AUD","LU2108987350.USD","LU0109391861.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113983849","title":"Rybrevant Faspro™关键数据公布：在治疗选择有限的晚期头颈癌中展现强劲且持久的疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1113983849","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113983849?lang=zh_cn&edition=full","pubTime":"2026-05-31 20:31","pubTimestamp":1780230674,"startTime":"0","endTime":"0","summary":"Rybrevant Faspro™（Amivantamab 与 Hyaluronidase-Lpuj 复方制剂）的关键临床试验数据表明，该药物在治疗选择仍然有限的晚期头颈癌患者中，能够产生强劲且持久的治疗应答。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2430703251.USD","LU2750360997.AUD","IE00B19Z3581.USD","LU0345770993.USD","IE0034235303.USD","BK4592","LU2430703178.SGD","LU2403377893.USD","LU2417539215.USD","BK4504","LU2471134952.CNY","LU2505996681.GBP","IE000M9KFDE8.USD","SGXZ57979304.SGD","LU1043141123.HKD","LU1162221912.USD","LU1061106388.HKD","LU0203347892.USD","LU2213496289.HKD","LU0964807845.USD","LU1244550221.USD","BK4581","LU1121112475.USD","IE00B7SZLL34.SGD","LU2471134523.USD","LU0689472784.USD","LU2456880835.USD","LU2750360641.GBP","LU2129689514.USD","IE000MB6IJN5.SGD","IE00BJT1NW94.SGD","IE000SO60NU8.SGD","IE00BLSP4239.USD","LU1732800096.USD","LU2112291526.USD","LU0689626769.HKD","LU1718418525.SGD","LU0124676726.USD","LU1551013342.USD","LU1914381329.SGD","BK4532","BK4550","LU1228905037.USD","IE00BN8TJ469.HKD","LU1585245621.USD","IE00BFXG1179.USD","LU0882574055.USD","IE00B42XCP33.USD","LU1496350502.SGD","IE0001KFT4U8.USD","LU1066051811.HKD","LU0426417589.USD","LU1674673691.USD","LU2129689605.HKD","IE00BVYPNV92.GBP","LU0210536198.USD","LU1983299246.USD","LU0820561818.USD","IE00BJJMRZ35.SGD","LU0795875169.SGD","IE00B19Z3B42.SGD","SG9999013999.USD","LU2592432038.USD","LU2505996509.AUD","LU1674673428.USD","LU1551013425.SGD","IE000WAW04H5.SGD","LU1196500208.SGD","IE00B4R5TH58.HKD","BK4534","BK4585","LU2471134879.HKD","LU1430594728.SGD","LU1261432733.SGD","LU1066051225.USD","IE00BLSP4452.SGD","LU0994945656.USD","IE00BDGV0183.EUR","LU0070217475.USD","IE0002141913.USD","LU1074936037.SGD","LU1032955483.USD","LU1221951046.USD","LU2896262040.SGD","IE000F7OJYX1.SGD","IE00B2B36J28.USD","LU0820562030.AUD","LU2236285917.USD","SG9999001440.SGD","IE00B3T34201.USD","LU2602419157.SGD","IE00BKVL7J92.USD","LU1023059063.AUD","LU0787776722.HKD","BK4568","LU1066051498.USD","LU2471134796.USD","LU0545562505.USD","LU1935042991.SGD","SG9999002224.SGD","LU0792757196.USD","LU0820561909.HKD","LU1778281490.HKD","LU1894683264.USD","LU2756315664.SGD","LU1280957306.USD","IE00BFTCPJ56.SGD","LU2430703095.HKD","IE00B3PB1722.GBP","IE00BBT3K403.USD","JNJ","LU0053666078.USD","LU0122379950.USD","LU0345770308.USD","LU1066053197.SGD","LU0640476718.USD","LU1629891620.HKD","LU0210528500.USD","LU2133065610.SGD","IE00BSNM7G36.USD","LU0203345920.USD","LU1059921491.USD","BK4588","LU1506573853.SGD","LU2347655156.SGD","LU0466842654.USD","LU1929549753.HKD","LU1032466523.USD","IE00B1BXHZ80.USD","LU1732799900.SGD","LU1894683348.USD","LU0943347566.SGD","LU0345769128.USD","LU1244550577.SGD","LU1145028129.USD","LU0234570918.USD","LU0234572021.USD","LU1221951129.SGD","LU0426412945.USD","LU0889566641.SGD","SG9999002232.USD","LU0432979614.USD","SG9999001176.SGD","IE0002270589.USD","LU0114720955.EUR","LU0912757837.SGD","LU2129689431.USD","LU0683600562.USD","LU0289739699.SGD","IE0000B7K699.USD","LU0345769631.USD","LU2487616109.SGD","IE00BZ1G4Q59.USD","LU0058720904.USD","LU0320765646.SGD","SG9999001176.USD","LU2089984988.USD","LU1244550494.USD","LU1043141396.HKD","IE0009355771.USD","LU1267930813.SGD","IE000BZT7R73.USD","BK4559","BK4533","LU1057294990.SGD","IE00BGHQF631.EUR","LU0985320562.USD","LU1228905540.USD","LU2023250330.USD","LU2756315318.SGD","IE00BVYPNW00.USD","LU0795875086.SGD","LU2468319806.SGD","LU0098860793.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639749602","title":"数据：某巨鲸向 HyperLiquid 存入 312 万美元 USDC，买入 4.59 万枚 HYPE","url":"https://stock-news.laohu8.com/highlight/detail?id=2639749602","media":"链捕手","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639749602?lang=zh_cn&edition=full","pubTime":"2026-05-31 08:43","pubTimestamp":1780188225,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据 Onchain Lens 监测，某巨鲸向 HyperLiquid 存入 312 万美元 USDC，并以 68.09 美元价格买入 4.5887 万枚 HYPE。 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2268300","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYPD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0173},{"period":"1month","weight":0.0526},{"period":"3month","weight":0.115},{"period":"6month","weight":0.1092},{"period":"1year","weight":0.287},{"period":"ytd","weight":0.1124}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"name":"制药","nameEN":"BK4007"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"制药(BK4007)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供制药(BK4007)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"制药,BK4007,制药股票,制药股票老虎,制药股票老虎国际,制药行情,制药股票行情,制药股价,制药股市,制药股票价格,制药股票交易,制药股票购买,制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"制药(BK4007)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供制药(BK4007)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}